Connect Biopharma Holdings Limited (CNTB): Price and Financial Metrics

Connect Biopharma Holdings Limited (CNTB): $1.18

0.02 (+1.72%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add CNTB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#108 of 341

in industry

CNTB Price/Volume Stats

Current price $1.18 52-week high $2.84
Prev. close $1.16 52-week low $0.68
Day low $1.15 Volume 26,800
Day high $1.24 Avg. volume 83,398
50-day MA $1.25 Dividend yield N/A
200-day MA $1.36 Market Cap 65.20M

CNTB Stock Price Chart Interactive Chart >


Connect Biopharma Holdings Limited (CNTB) Company Bio


Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.


CNTB Latest News Stream


Event/Time News Detail
Loading, please wait...

CNTB Latest Social Stream


Loading social stream, please wait...

View Full CNTB Social Stream

CNTB Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!